503A and 503B Pharmacies: What the Two Categories Actually Are

The short answer

A 503A pharmacy compounds a drug for one identified patient, after receiving a prescription for that patient. Its day-to-day oversight comes mainly from its state board of pharmacy. FDA describes section 503A as setting the conditions under which a compounded drug is exempt from premarket approval, from current good manufacturing practice requirements, and from labeling with adequate directions for use.

A 503B outsourcing facility is a different arrangement. It registers with FDA, may distribute compounded drugs without a patient-specific prescription, and is subject to current good manufacturing practice requirements. FDA inspects these facilities on a risk-based schedule and requires them to report adverse events.

Both names come from sections of the Federal Food, Drug, and Cosmetic Act. Neither category produces an FDA-approved product. FDA states it directly: compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before they are marketed.

Where the two categories came from

The split is recent, and it exists because of a disaster. FDA records that in 2012, contaminated drugs compounded by a Massachusetts pharmacy led to more than 750 cases of infection and more than 60 patient deaths across 20 states.

Congress responded with the Drug Quality and Security Act, enacted in November 2013. It left section 503A in place, removing only advertising provisions that had been found unconstitutional. That removal settled a long-running question about whether 503A was still valid law.

The same act added section 503B and created outsourcing facilities as a new, voluntary category. So the two are not two grades of the same license. One is the traditional pharmacy exemption; the other is an opt-in federal register with manufacturing obligations attached.

What a 503A pharmacy is exempt from, and what it is not

The exemptions are specific and conditional. To qualify, the drug must be compounded by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a physician. It must also be compounded on receipt of a valid prescription for an individual patient. That prescription condition is the load-bearing one.

Current good manufacturing practice requirements do not apply to drugs compounded under section 503A. FDA says so plainly, and it is the sharpest difference between the two categories.

Other federal law still applies regardless of category, including provisions on insanitary conditions. FDA also conducts surveillance and for-cause inspections of state-licensed pharmacies that are not registered as outsourcing facilities. State primacy is not the same as federal absence.

There is also a limit on copying. Section 503A restricts compounding drugs that are essentially copies of a commercially available drug, though a certain amount is permitted as long as it is not done regularly or in inordinate amounts.

What a 503B outsourcing facility takes on

An outsourcing facility accepts a heavier set of obligations in exchange for a wider distribution model. It may supply compounded drugs against a patient-specific prescription, or fill an order from a health care provider such as a hospital that is not for an identified individual patient.

In return, current good manufacturing practice requirements do apply. FDA inspects on a risk-based schedule, requires adverse event reporting, and requires certain information about the products the facility compounds.

There is a further constraint on what a 503B facility may make from bulk drug substances. It may use a bulk substance in only two situations. Either that substance appears on FDA's 503B bulks list, or the drug compounded from it is on FDA's shortage list at the time of compounding, distribution and dispensing.

That is a real bar, and it is higher than the 503A bar for manufacturing oversight. It still does not make the product FDA-approved.

What you can look up yourself, in a few minutes

The outsourcing facility question is the easiest one to answer, because FDA publishes the answer. The agency maintains a table of facilities registered under section 503B and updates it weekly.

That table carries more than names. For each facility it lists the initial and most recent registration dates and the date of the last inspection. It also shows whether a Form 483 was issued, whether a recall was conducted, and the action taken after that inspection. A facility that has never been inspected is shown as not yet inspected rather than left blank.

For a 503A pharmacy, the equivalent is the state board of pharmacy that licenses it. Boards publish license lookups, and a pharmacy that names itself can be confirmed there.

One reason to check rather than assume: FDA has reported fraudulent compounded semaglutide and tirzepatide carrying false label information. In some cases the pharmacy named on the label does not exist. In others the label names a real licensed pharmacy that did not compound the product.

What neither category changes

Approval status is the first thing that does not move. A compounded drug is not FDA-approved whichever section it was made under. FDA's stated position is that compounded drugs should only be used for patients whose medical needs cannot be met by an available FDA-approved drug.

Biologics are the second. FDA says biological products are not eligible for the compounding exemptions under either section, because federal law provides no pathway for marketing a biologic prepared outside an approved biologics license application.

Adverse-event visibility is the third, and it is uneven between the two. Federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA, so the agency has said reports from that side are likely undercounted.

The questions that get you a real answer

Ask which pharmacy or facility prepares and ships the product, by name and by city. A name is what makes every other question answerable.

Ask whether that entity is a state-licensed pharmacy compounding under section 503A or an outsourcing facility registered under section 503B. Then confirm the answer against FDA's registration table or the relevant state board rather than against the marketing page.

Ask what the active ingredient will be exactly as printed on the label, and whether anything else is in the vial. Ask who answers a question about the product itself, since that is often the pharmacy rather than the prescriber.

A program that answers those plainly has told you how it operates. A program that will not name the pharmacy has told you something as well.